Sleep Promotion and Pediatric Hypertension
Sleep Promotion Among Children Newly Diagnosed With Essential Hypertension
Children's Hospital of Philadelphia
10 participants
Feb 16, 2026
INTERVENTIONAL
Conditions
Summary
Determine the effectiveness and feasibility of a mobile health sleep extension approach in the pediatric nephrology setting, to increase sleep duration and reduce systolic and diastolic blood pressure.
Eligibility
Inclusion Criteria8
- Speak, read and write in English.
- Parental/guardian permission (informed consent) and child assent.
- Have a computer or a tablet computer with access to the Internet or own a smartphone with a data and text plan.
- Parent reported sleep duration on school nights less than or equal to 7.5 hours.
- Recently diagnosed with essential hypertension by Ambulatory Blood Pressure Monitoring (ABPM).
- If taking over the counter sleep aides, willing to stop them over the course of the study.
- Be the parent/guardian of an eligible child enrolled in the main study.
- Speak, read, and write in English.
Exclusion Criteria3
- Any clinically diagnosed sleep disorder (e.g. sleep apnea) in the electronic health record and or regular use of prescribed sleep aide.
- Underlying chronic medical conditions, defined as a medical condition with a duration or expected duration longer than 3 months that involved taking regular medication, taking medications that could affect blood pressure (e.g., anti-hypertensive medications, glucocorticoids, or stimulants), and patients with underlying diagnoses known to be associated with elevated blood pressure (e.g., cardiac disease, kidney disease or diabetes).
- \- Limited English proficiency
Interventions
During a 7-week intervention phase, parent-child dyads will be provided a sleep duration goal paired with a loss-framed financial incentive (virtual account) starting with deductions each time the sleep goal is not met, will be sent sleep guidance text messages, and will receive weekly performance feedback text messages.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06642246